Literature DB >> 25117207

The neurosteroid 5β-pregnan-3α-ol-20-one enhances actions of etomidate as a positive allosteric modulator of α1β2γ2L GABAA receptors.

P Li1, J R Bracamontes, B D Manion, S Mennerick, J H Steinbach, A S Evers, G Akk.   

Abstract

BACKGROUND AND
PURPOSE: Neurosteroids potentiate responses of the GABAA receptor to the endogenous agonist GABA. Here, we examined the ability of neurosteroids to potentiate responses to the allosteric activators etomidate, pentobarbital and propofol. EXPERIMENTAL APPROACH: Electrophysiological assays were conducted on rat α1β2γ2L GABAA receptors expressed in HEK 293 cells. The sedative activity of etomidate was studied in Xenopus tadpoles and mice. Effects of neurosteroids on etomidate-elicited inhibition of cortisol synthesis were determined in human adrenocortical cells. KEY
RESULTS: The neurosteroid 5β-pregnan-3α-ol-20-one (3α5βP) potentiated activation of GABAA receptors by GABA and allosteric activators. Co-application of 1 μM 3α5βP induced a leftward shift (almost 100-fold) of the whole-cell macroscopic concentration-response relationship for gating by etomidate. Co-application of 100 nM 3α5βP reduced the EC50 for potentiation by etomidate of currents elicited by 0.5 μM GABA by about three-fold. In vivo, 3α5βP (1mg kg(-1) ) reduced the dose of etomidate required to produce loss of righting in mice (ED50 ) by almost 10-fold. In tadpoles, the presence of 50 or 100 nM 3α5βP shifted the EC50 for loss of righting about three- or ten-fold respectively. Exposure to 3α5βP did not influence inhibition of cortisol synthesis by etomidate. CONCLUSIONS AND IMPLICATIONS: Potentiating neurosteroids act similarly on orthosterically and allosterically activated GABAA receptors. Co-application of neurosteroids with etomidate can significantly reduce dosage requirements for the anaesthetic, and is a potentially beneficial combination to reduce undesired side effects.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117207      PMCID: PMC4294051          DOI: 10.1111/bph.12861

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.

Authors:  Guo-Dong Li; David C Chiara; Gregory W Sawyer; S Shaukat Husain; Richard W Olsen; Jonathan B Cohen
Journal:  J Neurosci       Date:  2006-11-08       Impact factor: 6.167

Review 4.  Binding, activation and modulation of Cys-loop receptors.

Authors:  Paul S Miller; Trevor G Smart
Journal:  Trends Pharmacol Sci       Date:  2010-01-25       Impact factor: 14.819

Review 5.  In patients with severe sepsis, does a single dose of etomidate to facilitate intubation increase mortality?

Authors:  Benton R Hunter; Jonathan Kirschner
Journal:  Ann Emerg Med       Date:  2013-03-05       Impact factor: 5.721

6.  Neurosteroid analogues. 16. A new explanation for the lack of anesthetic effects of δ(16)-alphaxalone and identification of a δ(17(20)) analogue with potent anesthetic activity.

Authors:  Eva Stastna; Kathiresan Krishnan; Brad D Manion; Amanda Taylor; Nigam P Rath; Zi-Wei Chen; Alex S Evers; Charles F Zorumski; Steven Mennerick; Douglas F Covey
Journal:  J Med Chem       Date:  2011-05-06       Impact factor: 7.446

Review 7.  Etomidate for critically ill patients. Pro: yes we can use it.

Authors:  David C Ray; Dermot W McKeown
Journal:  Eur J Anaesthesiol       Date:  2012-11       Impact factor: 4.330

8.  Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human α1β3γ2 γ-aminobutyric acid type A (GABAA) receptor.

Authors:  David C Chiara; Selwyn S Jayakar; Xiaojuan Zhou; Xi Zhang; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

9.  The benzodiazepine diazepam potentiates responses of α1β2γ2L γ-aminobutyric acid type A receptors activated by either γ-aminobutyric acid or allosteric agonists.

Authors:  Ping Li; Megan M Eaton; Joe Henry Steinbach; Gustav Akk
Journal:  Anesthesiology       Date:  2013-06       Impact factor: 7.892

Review 10.  The role of neuroactive steroids in ethanol/stress interactions: proceedings of symposium VII at the Volterra conference on alcohol and stress, May 2008.

Authors:  A Leslie Morrow; Giovanni Biggio; Mariangela Serra; Howard C Becker; Marcelo F Lopez; Patrizia Porcu; Sarah E Alward; Todd K O'Buckley
Journal:  Alcohol       Date:  2009-11       Impact factor: 2.405

View more
  10 in total

Review 1.  New insights in the systemic and molecular underpinnings of general anesthetic actions mediated by γ-aminobutyric acid A receptors.

Authors:  Bernd Antkowiak; Uwe Rudolph
Journal:  Curr Opin Anaesthesiol       Date:  2016-08       Impact factor: 2.706

2.  Synaptic-type α1β2γ2L GABAA receptors produce large persistent currents in the presence of ambient GABA and anesthetic drugs.

Authors:  Ping Li; Gustav Akk
Journal:  Mol Pharmacol       Date:  2015-02-09       Impact factor: 4.436

3.  Binding site location on GABAA receptors determines whether mixtures of intravenous general anaesthetics interact synergistically or additively in vivo.

Authors:  Daniel E Kent; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

4.  Analysis of GABAA Receptor Activation by Combinations of Agonists Acting at the Same or Distinct Binding Sites.

Authors:  Daniel J Shin; Allison L Germann; Douglas F Covey; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-18       Impact factor: 4.436

5.  Synthesis and pharmacological evaluation of neurosteroid photoaffinity ligands.

Authors:  Pavel Y Savechenkov; David C Chiara; Rooma Desai; Alexander T Stern; Xiaojuan Zhou; Alexis M Ziemba; Andrea L Szabo; Yinghui Zhang; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik
Journal:  Eur J Med Chem       Date:  2017-04-21       Impact factor: 6.514

6.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

Review 7.  Comparison of αβδ and αβγ GABAA receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics.

Authors:  Hua-Jun Feng; Stuart A Forman
Journal:  Pharmacol Res       Date:  2017-12-30       Impact factor: 7.658

8.  Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant α1β3γ2L GABAA Receptors Indicates Selectivity and Crosstalk among Intersubunit Transmembrane Anesthetic Sites.

Authors:  Andrea Szabo; Anahita Nourmahnad; Elizabeth Halpin; Stuart A Forman
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

9.  Alphaxalone Binds in Inner Transmembrane β+-α- Interfaces of α1β3γ2 γ-Aminobutyric Acid Type A Receptors.

Authors:  Alexis M Ziemba; Andrea Szabo; David W Pierce; Marian Haburcak; Alex T Stern; Anahita Nourmahnad; Elizabeth S Halpin; Stuart A Forman
Journal:  Anesthesiology       Date:  2018-02       Impact factor: 7.892

10.  Enhanced GABAergic actions resulting from the coapplication of the steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam.

Authors:  Lily Q Cao; Michael C Montana; Allison L Germann; Daniel J Shin; Sampurna Chakrabarti; Steven Mennerick; Carla M Yuede; David F Wozniak; Alex S Evers; Gustav Akk
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.